0001140361-21-008343.txt : 20210312 0001140361-21-008343.hdr.sgml : 20210312 20210312163601 ACCESSION NUMBER: 0001140361-21-008343 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210308 FILED AS OF DATE: 20210312 DATE AS OF CHANGE: 20210312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BALTHROP PATRICK J CENTRAL INDEX KEY: 0001284839 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36200 FILM NUMBER: 21737973 MAIL ADDRESS: STREET 1: 243 LEEDS COURT CITY: LAKE BLUFF STATE: IL ZIP: 60044 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oxford Immunotec Global PLC CENTRAL INDEX KEY: 0001586049 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ BUSINESS PHONE: 44 01235 442780 MAIL ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ 4 1 form4.xml FORM 4 X0306 4 2021-03-08 true 0001586049 Oxford Immunotec Global PLC OXFD 0001284839 BALTHROP PATRICK J C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE X0 OX14 4RZ UNITED KINGDOM true Ordinary Shares 2021-03-08 4 D 0 8081 22 D 0 D Stock Option (Right to Buy) 11.62 2021-03-08 4 D 0 3728 10.38 D 2026-01-29 Ordinary Shares 3728 0 D Stock Option (Right to Buy) 11.62 2021-03-08 4 D 0 14914 10.38 D 2026-01-29 Ordinary Shares 14914 0 D Stock Option (Right to Buy) 8.65 2021-03-08 4 D 0 7457 13.35 D 2026-06-28 Ordinary Shares 7457 0 D Stock Option (Right to Buy) 14.46 2021-03-08 4 D 0 7457 7.54 D 2027-06-06 Ordinary Shares 7457 0 D Stock Option (Right to Buy) 14.49 2021-03-08 4 D 0 7457 7.51 D 2028-06-19 Ordinary Shares 7457 0 D Stock Option (Right to Buy) 14.44 2021-03-08 4 D 0 7457 7.56 D 2029-06-18 Ordinary Shares 7457 0 D Stock Option (Right to Buy) 12.96 2021-03-08 4 D 0 9494 9.04 D 2030-06-24 Ordinary Shares 9494 0 D Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. /s/ Matthew T E McLaughlin, as Attorney-in-Fact for Patrick J. Balthrop, Sr. 2021-03-12